OBX — Obsidian Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 2130606 ·
Last close
$12.07
Market Cap
$745.61M
52W High
$49.97
52W Low
$9.60
ADV30
498,061
Next earnings
—
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that leverage mbIL15 to enhance persistence, antitumor activity, and clinical safety. Access to investigational therapies is currently limited to participation in clinical trials, and the company collaborates with other organizations to apply its platform technology. The company was founded in 2015 and is based in Cambridge, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Mar 2026 0 — -20,280,000 -19,633,000 70,136,000 26,439,000 346,333,000
Mar 2025 0 — -26,603,000 -24,986,000 — — —

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-46,381,000
Investing CF
$21,502,000
Financing CF
$53,000
CapEx
$-56,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.72
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-315,568,000
Inventory
—
Receivables
—
ST Investments
$32,317,000
EBIT TTM
$-46,883,000
Pretax Income TTM
$-44,619,000
Interest Exp TTM
—
Analysts
3

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -105,667,000 -100,607,000 88,580,000 354,617,000 -266,037,000 -90,393,000
Dec 2024 0 -91,255,000 -83,109,000 183,713,000 358,144,000 -174,431,000 -75,002,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$0
Forward EPS
$-2.13

Peers — same industry

TickerNameMarket CapLastDaily %
APMD Apnimed, Inc. $741.03M $17.80 —
IVEVF Inventiva S.A. $751.18M $3.18 —
PAHC PHIBRO ANIMAL HEALTH CORP $737.01M $34.92 —
IVA Inventiva S.A. $760.63M $3.22 —
SGMT Sagimet Biosciences Inc. $702.97M $9.85 —

News headlines (Yahoo Finance, 1h cache)

Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
2026-11-12 21:05 · Yahoo
Obsidian Therapeutics to Present Updated Amsoki-cel Efficacy and Pooled Safety Data in Advanced Melanoma at SITC 2026 Annual Meeting
2026-11-06 14:05 · Yahoo
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
2026-10-02 13:05 · Yahoo
Obsidian Therapeutics (OBX) Stock Dropped, So What Is Behind The Attention Now?
2026-08-13 01:11 · Yahoo
Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls
2026-08-06 13:48 · Yahoo
Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls
2026-08-05 13:40 · Yahoo
Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma
2026-08-05 11:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.